Skip to main content
. Author manuscript; available in PMC: 2022 Sep 7.
Published in final edited form as: Exp Parasitol. 2021 Jul 17;228:108135. doi: 10.1016/j.exppara.2021.108135

Table 2. Parasitological and clinical effects of Trypanosoma brucei rhodesiense strains on mouse.

Parasitological and Clinical Parameters Control KETRI
3801
KETRI
2636
EATRO
1762
KETRI
3928
Median pre-patent period (IQR) N/A 3(3–3) 4(3–5) 3(3–4) 4.5(4–8)a
First peak parasitaemia (dpi) N/A 4 6 6 20
Clinical signs (days) N/A 7 8 9 33
% PCV change at day 14 dpi −2.42 −26.51 −25.48 −20.70 −3.68
% PCV change before extremis −4.09 (56) −26.51 (14) −23.95 (28) −17.58 (35) −22.43 (56)
% Weight change 16.21 −24.12 −19.75 −17.79 13.84
Median survival time (days) N/A 20 33 35 -

IQR: interquartile range.

dpi: days post infection.

First peak parasitaemia considered at level of ≥ antilog 7, and more often followed by reduction in parasite numbers.

Clinical signs observed include rough or poor coat condition and pallor of skin, reduced activity, hunched appearance, laboured breathing and crowding.

The values are estimated from Fig. 3.

a

Of the 10 mice, the pre-patent period of one animal was 17 days, and clearly an outlier.